Reviewer’s report

Title: 5-alpha Reductase Inhibitors and Prostate Cancer Prevention: where do we turn now?

Version: 2 Date: 31 May 2011

Reviewer: Claus G Roehrborn

Reviewer’s report:

Major Compulsory Revisions

Minor Essential Revisions
- A table comparing the two trials would be helpful

Discretionary Revisions
- I recommend to at least cite some of the cost effectiveness articles published to also address that thorny issue
- I recommend to provide actual numbers for the high risk cancers since the reader should understand the magnitude of the GS 8-10 cancer issue

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.